794 related articles for article (PubMed ID: 24315769)
1. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
Jin K; Park BS; Kim YW; Vaziri ND
Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
[TBL] [Abstract][Full Text] [Related]
2. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
4. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
5. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
6. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
[TBL] [Abstract][Full Text] [Related]
7. Effects of lipoprotein apheresis on PCSK9 levels.
Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
[TBL] [Abstract][Full Text] [Related]
8. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
9. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
Liu S; Vaziri ND
Nephrol Dial Transplant; 2014 Mar; 29(3):538-43. PubMed ID: 24166456
[TBL] [Abstract][Full Text] [Related]
10. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
11. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
[TBL] [Abstract][Full Text] [Related]
12. Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.
Shen H; Feng S; Lu Y; Jiang L; Yang T; Wang Z
Ren Fail; 2020 Nov; 42(1):405-412. PubMed ID: 32349585
[No Abstract] [Full Text] [Related]
13. Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants.
Araki S; Suga S; Miyake F; Ichikawa S; Kinjo T; Yamamoto Y; Kusuhara K
Early Hum Dev; 2014 Oct; 90(10):607-11. PubMed ID: 25134067
[TBL] [Abstract][Full Text] [Related]
14. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
15. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
Miyoshi T; Nakamura K; Doi M; Ito H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
[TBL] [Abstract][Full Text] [Related]
16. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
18. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
Kwakernaak AJ; Lambert G; Slagman MC; Waanders F; Laverman GD; Petrides F; Dikkeschei BD; Navis G; Dullaart RP
Atherosclerosis; 2013 Feb; 226(2):459-65. PubMed ID: 23261172
[TBL] [Abstract][Full Text] [Related]
19. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
[TBL] [Abstract][Full Text] [Related]
20. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
